SCHEMBL6317258

SCHEMBL6317258

O=C(O)C(Cc1ccccc1)N(Cc1sccc1-c1ccc(F)cc1)C(=O)c1ccc(Cl)cc1Cl

nearest known ligand 0.60

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 1/20 0.39
PTPN1 P18031 1/20 0.39
AGTR1 P30556 1/20 0.38
ADAMTS5 Q9UNA0 1/20 0.37
KIF11 P52732 1/20 0.36
ANO1 Q5XXA6 1/20 0.36
SHMT1 P34896 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6326003 0.93 KIF11 (0.36) CYP3A4PTPN1ADAMTS5KIF11SHMT1
SCHEMBL6318551 0.93 KIF11 (0.36) CYP3A4PTPN1ADAMTS5KIF11SHMT1
SCHEMBL6318059 0.92 KIF11 (0.37) CYP3A4PTPN1ADAMTS5KIF11SHMT1
SCHEMBL6318056 0.92 KIF11 (0.37) CYP3A4PTPN1ADAMTS5KIF11SHMT1
SCHEMBL6324968 0.91 RORB (0.37) KIF11SHMT1
SCHEMBL6317863 0.91 PPARA (0.38) PTPN1ADAMTS5KIF11SHMT1
SCHEMBL6324965 0.91 RORB (0.37) KIF11SHMT1
SCHEMBL6317861 0.91 PPARA (0.38) PTPN1ADAMTS5KIF11SHMT1
SCHEMBL6318428 0.90 KIF11 (0.38) PTPN1KIF11SHMT1
SCHEMBL6317221 0.90 RORB (0.41) PTPN1ADAMTS5KIF11SHMT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 344 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160200009-A1 A STABILISER MOUNTING MANDREL, AND A METHOD OF FORMING A STABILISER MOUNTING MANDREL ON A DRILLING OR CASING DRILLING OR RUNNING CASING TUBULAR TDTECH LIMITED (NZ) 2016-07-14 US claimed
CN-1268317-C Cosmetic composition material containing exogenous ligand-receptor system and its application OREAL (FR) 2006-08-09 CN claimed
US-6887877-B2 Compounds and methods for the treatment or prevention of Flavivirus infections VIROCHEM PHARMA INC. (CA) 2005-05-03 US claimed
CN-1494893-A Cosmetic composition material containing exogenous ligand-receptor system and its application ���ŷ� 2004-05-12 CN claimed
US-20030229053-A1 Compounds and methods for the treatment or prevention of flavivirus infections SHIRE BIOCHEM INC. (CA) 2003-12-11 US claimed
WO-2003091301-A2 BLENDS OF FLUOROPOLYMER AND PLASTICIZED POLYVINYL CHLORIDE TEKNOR APEX COMPANY (US) 2003-11-06 WO claimed
US-20030204021-A1 Blends of fluoropolymer and plasticized polyvinyl chloride TEKNOR APEX COMPANY 2003-10-30 US claimed
CN-1451370-A Cosmetics composition and method for treating hair using same OREAL (FR) 2003-10-29 CN claimed
US-RE33839-E A disposable product composed of crosslinked natural or synthetic polymers and a water soluble pourable powder of an organic or inorganic compound CHEMISCHE FABRIK STOCKHAUSEN GMBH (DE) 1992-03-03 US claimed
US-4693713-A DISPOSAL PRODUCT CHEMISCHE FABRIK STOCKHAUSEN GMBH, BAKERPFAD 25, D-4150 KREFELD A GERMAN CORP. 1987-09-15 US claimed
JP-6218884-A None JP disclosed
US-12641976-B2 Display device test portion and production method for same Sharp Display Technology Corporation (JP) 2026-05-26 US disclosed
US-20260136793-A1 DISPLAY DEVICE SHARP KK (JP) 2026-05-14 US disclosed
CN-117561559-B Method for manufacturing display device 夏普显示科技株式会社 2026-05-12 CN disclosed
CN-117651984-B Display device 夏普显示科技株式会社 2026-05-12 CN disclosed
US-6525465-B1 Cesium-, rubidium-, or potassium bromide or iodide SHARP KABUSHIKI KAISHA (JP) 2003-02-25 US disclosed
WO-2002100846-A1 COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS SHIRE BIOCHEM INC. (CA) 2002-12-19 WO disclosed
EP-0659772-B1 Multifunctional viscosity index improvers DSM COPOLYMER INC (US) 1998-09-09 EP disclosed
CN-1160062-A Manufacturing method for polycarbonate GEN ELECTRIC (US) 1997-09-24 CN disclosed
JP-H06218884-A MATERIAL FOR PRODUCING PROTECTIVE MEANS AGAINST NUCLEAR, BIOLOGICAL AND CHEMICAL ATTACKS MANUFACTURE DE VETEMENTS PAUL BOYE SA 1994-08-09 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260136793-A1 DISPLAY DEVICE L1CAM, PTPRJ, EPHA4 CYP3A4 3224/4885PTPN1 52/4885AGTR1 1617/4885
US-12641976-B2 Display device test portion and production method for same TES, ITK, EPHA4 CYP3A4 2289/4885PTPN1 70/4885AGTR1 4790/4885
US-20030229053-A1 Compounds and methods for the treatment or prevention of flavivirus infections HAVCR2, ZC3HAV1, MAVS CYP3A4 452/4885PTPN1 1268/4885AGTR1 1153/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.